| 1 |
Bray F, Ferlay J, Soerjomataram I, et al. Erratum: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA: A Cancer J for Clin, 2020, 68: 394-424.
|
| 2 |
Zhang S, Sun K, Zheng R, et al. Cancer incidence and mortality in China, 2015[J]. Journal of the National Cancer Center, 2020, 1(1): 2-11.
|
| 3 |
Morton D. FOxTROT: An international randomised controlled trial in 1053 patients evaluating neoadjuvant chemotherapy (NAC) for colon cancer. On behalf of the FOxTROT Collaborative Group[J]. Ann Oncol, 2019, 30: v198.
|
| 4 |
Cercek A, Dos Santos Fernandes G, Roxburgh CS, et al. Mismatch repair-deficient rectal cancer and resistance to neoadjuvant chemotherapy[J]. Clin Cancer Res, 2020, 26(13): 3271-3279.
|
| 5 |
Benson AB, Venook AP, Al-Hawary MM, et al. Rectal cancer, version 2.2018[J]. NCCN Clinical Practice Guidelines in Oncology, 2020: 874-901.
|
| 6 |
Al-Sukhni E, Attwood K, Mattson DM, et al. Predictors of pathologic complete response following neoadjuvant chemoradiotherapy for rectal cancer[J]. Ann Surg Oncol, 2016, 23(4): 1177-1186.
|
| 7 |
Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair deficient/microsatellite instability-high colorectal cancer (CheckMate 142): results of an open-label, multicenter, phase 2 study[J]. Lancet Oncology, 2017, 18(9): 1182-1191.
|
| 8 |
Luchini C, Bibeau F, Ligtenberg MJL, et al. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach[J]. Ann Oncol, 2019, 30(8): 1232-1243.
|
| 9 |
Li SKH, Martin A. Mismatch repair and colon cancer: mechanisms and therapies explored[J]. Trends Mol Med, 2016, 22(4): 274-289.
|
| 10 |
Tougeron D, Mouillet G, Trouilloudet I, et al. Efficacy of adjuvant chemotherapy in colon cancer with microsatellite instability: a large multicenter AGEO study[J]. J Natl Cancer Inst, 2016, 108(7): djv438.
|
| 11 |
Sargent DJ, Marsoni S, Monges G, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer[J]. J Clin Oncol, 2010, 28(20): 3219-3226.
|
| 12 |
Venderbosch S, Nagtegaal ID, Maughan TS, et al. Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies[J]. Clin Cancer Res, 2014, 20: 5322-5330.
|
| 13 |
Goldstein J, Tran B, Ensor J, et al. Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H) [J]. Ann Oncol, 2014, 25(5): 1032-1038.
|
| 14 |
Ganesh K, Stadler ZK, Cercek A, et al. Immunotherapy in colorectal cancer: rationale, challenges and potential[J]. Nat Rev Gastroenterol Hepatol, 2019, 16(6): 361-375.
|
| 15 |
Wu T, Wu X, Wang HY, et al. Immune contexture defined by single cell technology for prognosis prediction and immunotherapy guidance in cancer[J]. Cancer Commun (Lond), 2019, 39(1): 21.
|
| 16 |
Topalian SL, Taube JM, Pardoll DM, et al. Neoadjuvant checkpoint blockade for cancer immunotherapy[J]. Science, 2020, 367(6477): eaax0182.
|
| 17 |
Liu J, Blake SJ, Yong MC, et al. Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease[J]. Cancer Discov, 2016, 6(12): 1382-1399.
|
| 18 |
Wang F, Wang ZX, Chen G, et al. Expert opinions on immunotherapy for patients with colorectal cancer[J]. Cancer Communications, 2020, 4(10): 467-472.
|
| 19 |
Chalabi M, Fanchi LF, Dijkstra KK, et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers[J]. Nat Med, 2020, 26(4): 566-576.
|
| 20 |
Yuki S, Bando H, Tsukada Y, et al. Short-term results of VOLTAGE-A: Nivolumab monotherapy and subsequent radical surgery following preoperative chemoradiotherapy in patients with microsatellite stable and microsatellite instability-high locally advanced rectal cancer[J]. J Clin Oncol, 2020, 38(15_suppl): 4100.
|
| 21 |
Cheng YK, Qin QY, Huang XY, et al. Effect of interval between preoperative radiotherapy and surgery on clinical outcome and radiation proctitis in rectal cancer from FOWARC trial[J]. Cancer Med, 2020, 9(3): 912-919.
|
| 22 |
Deng YH, Chi P, Lan P, et al. Neoadjuvant modified FOLFOX6 with or without radiation versus fluorouracil plus radiation for locally advanced rectal cancer: final results of the chinese FOWARC trial[J]. J Clin Oncol, 2019, 37(34): 3223-3233.
|
| 23 |
Rahma OE, Hong TS, Russell MM, et al.NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy (TNT) in locally advanced rectal cancer (LARC)-First experimental arm(EA) initial results[J]. 2021, Journal of Clinical Oncology, 39(3_suppl): 8.
|
| 24 |
Zhang J, Cai J, Deng YH, et al. Complete response in patients with locally advanced rectal cancer after neoadjuvant treatment with nivolumab[J]. OncoImmunology, 2019, 8(12): e1663108,
|
| 25 |
Mans L, Pezzullo M, D'Haene N, et al. Pathological complete response after neoadjuvant immunotherapy for a patient with microsatellite instability locally advanced rectal cancer: should we adapt our standard management for these patients?[J]. European Journal of Cancer, 2020, 135: 75-77.
|
| 26 |
Zhang Z, Cheng S, Gong J, et al. Efficacy and safety of neoadjuvant immunotherapy in patients with microsatellite instability-high gastrointestinal malignancies: A case series[J]. Eur J Surg Oncol, 2020, 46(10 Pt B): e33-e39.
|
| 27 |
DemisseRahel, DamleNeha, Edward Kim, et al. Neoadjuvant immunotherapy–based systemic treatment in MMR-defificient or MSI-high rectal cancer: case series[J].J Natl Compr Canc Netw, 2020, 18(7): 798-804.
|
| 28 |
Liu DX, Li DD, He W, et al. PD-1 blockade in neoadjuvant setting of DNA mismatch repair-deficient/microsatellite instability-high colorectal cancer[J]. Oncoimmunology, 2020, 9(1): e1711650.
|